Down-regulation of glutamatergic terminals (VGLUT1) driven by Aβ in Alzheimer's disease
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Down-regulation of glutamatergic terminals (VGLUT1) driven by Aβ in Alzheimer's disease
Authors
Keywords
-
Journal
HIPPOCAMPUS
Volume 26, Issue 10, Pages 1303-1312
Publisher
Wiley
Online
2016-06-03
DOI
10.1002/hipo.22607
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Reduction in Post-Synaptic Scaffolding PSD-95 and SAP-102 Protein Levels in the Alzheimer Inferior Temporal Cortex is Correlated with Disease Pathology
- (2017) Dustin T. Proctor et al. JOURNAL OF ALZHEIMERS DISEASE
- Lipoic acid improves neuronal insulin signalling and rescues cognitive function regulating VGlut1 expression in high-fat-fed rats: Implications for Alzheimer's disease
- (2016) Manuel Rodriguez-Perdigon et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Alzheimer's disease-related amyloid-β induces synaptotoxicity in human iPS cell-derived neurons
- (2015) K Nieweg et al. Cell Death & Disease
- Perforant path synaptic loss correlates with cognitive impairment and Alzheimer's disease in the oldest-old
- (2014) John L. Robinson et al. BRAIN
- Altered synapses and gliotransmission in Alzheimer's disease and AD model mice
- (2013) Stanislaw Mitew et al. NEUROBIOLOGY OF AGING
- Predominant loss of glutamatergic terminal markers in a β-amyloid peptide model of Alzheimer's disease
- (2013) Paula M. Canas et al. NEUROPHARMACOLOGY
- Apolipoprotein E4 effects in Alzheimer’s disease are mediated by synaptotoxic oligomeric amyloid-β
- (2012) Robert M. Koffie et al. BRAIN
- Orchestrated experience-driven Arc responses are disrupted in a mouse model of Alzheimer's disease
- (2012) Nikita Rudinskiy et al. NATURE NEUROSCIENCE
- Glutamatergic alterations and mitochondrial impairment in a murine model of Alzheimer disease
- (2011) Tommaso Cassano et al. NEUROBIOLOGY OF AGING
- Preferential accumulation of amyloid-beta in presynaptic glutamatergic terminals (VGluT1 and VGluT2) in Alzheimer's disease cortex
- (2011) Sophie Sokolow et al. NEUROBIOLOGY OF DISEASE
- Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease
- (2010) Marcello D'Amelio et al. NATURE NEUROSCIENCE
- Vesicular glutamate transporter and cognition in stroke: A case-control autopsy study
- (2010) S. L. Kirvell et al. NEUROLOGY
- Increased Vulnerability to Depressive-Like Behavior of Mice with Decreased Expression of VGLUT1
- (2009) Alvaro L. Garcia-Garcia et al. BIOLOGICAL PSYCHIATRY
- Age-Dependent Impairment of Spine Morphology and Synaptic Plasticity in Hippocampal CA1 Neurons of a Presenilin 1 Transgenic Mouse Model of Alzheimer's Disease
- (2009) A. Auffret et al. JOURNAL OF NEUROSCIENCE
- Adenosine A2A Receptor Blockade Prevents Synaptotoxicity and Memory Dysfunction Caused by -Amyloid Peptides via p38 Mitogen-Activated Protein Kinase Pathway
- (2009) P. M. Canas et al. JOURNAL OF NEUROSCIENCE
- Reduced hippocampal glutamate in Alzheimer disease
- (2009) R. Rupsingh et al. NEUROBIOLOGY OF AGING
- Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior
- (2008) Dennis J. Selkoe BEHAVIOURAL BRAIN RESEARCH
- Widespread Changes in Dendritic Spines in a Model of Alzheimer's Disease
- (2008) S. Knafo et al. CEREBRAL CORTEX
- Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice
- (2008) R. Minkeviciene et al. JOURNAL OF NEUROCHEMISTRY
- Endocytosis Is Required for Synaptic Activity-Dependent Release of Amyloid-β In Vivo
- (2008) John R. Cirrito et al. NEURON
- Loss of VGLUT1 and VGLUT2 in the prefrontal cortex is correlated with cognitive decline in Alzheimer disease
- (2007) Alireza Kashani et al. NEUROBIOLOGY OF AGING
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started